What Happened in Semiconductor and Biomedical Device Funding?
The six-month period from 1 April to 1 October 2026 produced a notable collection of later-stage funding rounds across semiconductor and biomedical hardware startups.
The companies are not all pursuing the same market. Semiconductor startups are working on areas such as physical AI silicon, analog integrated circuits, timing solutions and high-speed interconnects. Biomedical device startups are developing technologies for neurological, cardiovascular, neurovascular and other clinical applications.
What connects these companies is the capital intensity of their technology and the increasingly important role of later-stage financing in moving physical products toward commercial scale.
Why Are Series B and Series C Rounds Important?
Early venture financing can help a startup prove that a technology works. Later financing often asks a different question: can the technology become a scalable business?
For semiconductor startups, that may involve moving from prototype silicon toward production, expanding design teams, developing the next chip generation or supporting customers adopting the technology.
For biomedical device companies, later-stage capital can support clinical trials, regulatory submissions, manufacturing systems, physician adoption and commercialization.
This distinction is important when reading funding news. Two companies can both announce a $50 million financing, yet the underlying capital requirements and milestones can be completely different.
The funding amount is the headline. The milestone behind the funding is often the more informative part of the story.
Semiconductor Startup Series B and Series C Funding
Semiconductor startups have attracted substantial investment as demand grows for specialized computing, physical AI, advanced connectivity and more efficient hardware architectures.
The recent funding activity also shows how broad the semiconductor category has become. It includes not only processors but also analog ICs, timing technologies, interconnects and supporting silicon infrastructure.
SiMa.ai announced a $150 million Series C financing on 28 September 2026. The round was co-led by Fidelity Management & Research Company and Amplify, with participation from additional investors.
The company develops purpose-built silicon and software for physical AI applications including robotics, drones and automotive systems.
The financing brings SiMa.ai's reported total capital raised to approximately $500 million and places the company among the most visible recent later-stage semiconductor funding stories.
Celera Semiconductor closed a $30 million Series B financing in August 2026, with Maverick Silicon providing the reported financing.
The company focuses on analog integrated circuits and uses AI-assisted approaches to accelerate analog chip development and design automation.
For semiconductor investors, the deal is notable because analog chips remain critical to real-world systems even as much of the semiconductor investment narrative has focused on AI accelerators.
Stathera announced a $55 million Series B financing on 30 June 2026. The round was led by Maverick Silicon with participation from Celesta Capital, BDC Capital, MediaTek Innovation Fund, TXC Corporation and Ultratech Capital Partners.
Stathera develops silicon timing solutions for applications including mobile, IoT and AI data-center systems.
The company's financing illustrates how semiconductor investment extends beyond computing cores. Timing and synchronization technologies can become important infrastructure as systems become faster and more complex.
AttoTude raised $52 million in Series C financing in June 2026.
The company is developing interconnect technology designed to transmit electrical signals directly over dielectric fiber, with an emphasis on AI infrastructure.
The financing demonstrates another direction in semiconductor infrastructure: improving how data moves between components rather than simply making the compute element faster.
The chip opportunity is no longer limited to the chip itself.
Recent Series B and Series C rounds span processors, analog ICs, timing and interconnect technology. Investors are therefore funding multiple layers of the hardware stack as specialized computing expands.
Biomedical Device Startups Raising Series B and C
The biomedical device funding picture has a different rhythm.
Companies can spend years moving through engineering, preclinical development, clinical trials, regulatory processes and manufacturing preparation before reaching broad commercialization.
That makes later-stage funding particularly informative. A Series B or Series C round can indicate that a company is attempting to finance a major transition in its development path.
CereVasc announced an $85 million Series C financing in June 2026.
The company is developing the eShunt System for communicating hydrocephalus and reported that the financing would support its STRIDE pivotal trial, regulatory activities and preparations for future commercialization.
The round illustrates why medical-device funding cannot be analysed solely by company valuation or headline capital. Clinical and regulatory milestones can be just as important when assessing where the capital is going.
XCath announced a $30 million Series C financing in April 2026.
The company is developing neuro-endovascular surgical robotics, with the financing supporting efforts to advance its technology toward clinical and commercial use.
Robotics is an important intersection between advanced hardware, software and medical devices. Tracking companies in this category can therefore reveal how capital is moving across multiple technology ecosystems at once.
RapidPulse closed an oversubscribed $48 million Series B financing in July 2026.
The company is developing aspiration technology for acute ischemic stroke treatment. Its reported plans for the financing include advancing its TURBO investigational study and expanding clinical experience.
The participation of Medtronic alongside financial investors also demonstrates how strategic corporate participation can appear in later-stage medical-device rounds.
Nervonik announced a $52.5 million Series B financing in April 2026.
The clinical-stage medical-device company is developing peripheral nerve stimulation technology that combines stimulation with sensing capabilities.
The round is another example of investors supporting medical hardware that combines electronics, sensing and therapeutic intervention.
Advanced NanoTherapies closed an oversubscribed Series B financing of more than $31 million in June 2026.
The company is developing a dual-drug nanoparticle coated balloon platform for cardiovascular applications.
This type of device-plus-drug technology highlights the increasingly interdisciplinary nature of biomedical hardware, where mechanical engineering, drug delivery and materials science can intersect in a single product.
Irish medtech company CroíValve secured approximately $36 million in Series B investment in June 2026, alongside additional grant-linked funding associated with the financing.
The company is developing the DUO system for minimally invasive treatment of tricuspid regurgitation.
The financing is intended to support expansion of its clinical program across the United States and Europe.
Butterfly Medical secured $21 million in Series C funding in May 2026.
The company is developing a minimally invasive implantable technology for benign prostatic hyperplasia.
The round demonstrates another characteristic of later-stage medical-device financing: investors may fund companies not only to develop the technology but also to advance regulatory, market-access and commercialization objectives.
What Does the Recent Funding Activity Reveal?
Looking at individual funding rounds is useful. Looking across them is where the investment-intelligence story becomes more interesting.
1. Physical Technology Requires Milestone Capital
Hardware startups often cannot scale simply by adding software engineers. They may need fabrication, manufacturing, testing, clinical studies, regulatory work, specialized equipment, supply-chain relationships and certification.
That makes financing milestones particularly important.
2. AI Is Expanding the Semiconductor Opportunity
The semiconductor deals in this period demonstrate that AI hardware investment is not restricted to one processor category.
Physical AI, timing, analog integrated circuits and interconnect technologies all represent different layers of the infrastructure required to build modern computing systems.
3. Medical Devices Are Moving Toward Larger, Milestone-Driven Rounds
Later-stage medtech funding can be tied closely to clinical and regulatory milestones.
In the recent examples, capital is being directed toward pivotal trials, regulatory preparation, commercialization, manufacturing and broader clinical adoption.
4. Strategic Investors Can Matter as Much as Financial Investors
Some biomedical rounds include participation from major healthcare companies or strategic investors.
Strategic participation can provide another layer of information for researchers because it may indicate relationships involving technology, distribution, clinical expertise or market access.
5. The Funding Network Matters
A company is rarely an isolated investment event.
Its investors connect it to other portfolio companies, sectors, technologies and financing relationships.
This is why a funding database can become much more valuable when it allows researchers to move from one funding event into the wider network around that event.
One funding round can become the starting point for a much larger research map.
Follow the company, investors, previous rounds, co-investors, sector, geography and subsequent funding activity to understand the network behind the headline.
How Investors Can Research Semiconductor and Biomedical Device Funding
Funding announcements are useful starting points, but they rarely provide the entire investment picture.
A deeper research process can examine several dimensions simultaneously.
- Company and founding team
- Funding history
- Series B and Series C participation
- Lead and participating investors
- Previous investors
- Co-investment relationships
- Sector and technology category
- Geographic concentration
- Clinical or product milestones
- Regulatory developments
- Manufacturing and commercialization plans
- Subsequent financing activity
This approach can reveal patterns that are difficult to see when funding announcements are examined one at a time.
For example, a researcher might identify an investor participating across several neurotechnology companies, a semiconductor investor repeatedly backing specialized silicon startups, or a particular geography attracting capital across multiple hardware categories.
Those connections can become useful signals for further investment research.
Questions Worth Asking Beyond the Funding Amount
A sophisticated funding analysis starts with the headline and then moves deeper.
Who led the round?
The lead investor can provide important context about the financing and the investor's interest in the company.
Who participated?
Existing investors, new investors and strategic participants can tell different stories about the company's financing network.
What is the capital being used for?
Product development, manufacturing, clinical trials and commercialization each imply different capital requirements and different stages of company development.
What happened before the round?
Previous funding can reveal how long a company has been financed, which investors have remained involved and how the capital structure has evolved.
What happens after the round?
Subsequent funding, partnerships, regulatory milestones, acquisitions and product launches can provide additional context after the original announcement.
The InveLedger Perspective
Semiconductor and biomedical device startups operate in different markets, but they share an important characteristic: technology alone does not tell the complete investment story.
Capital, investors, development milestones, commercial relationships and market timing all interact.
A semiconductor Series C can point toward a transition into the next stage of chip development and commercial scale.
A biomedical-device Series B can finance clinical validation, while a Series C may support regulatory and commercialization efforts.
The meaning of the round therefore depends on the company and its position in its development cycle.
This is where investment intelligence becomes useful. Instead of asking only:
"Who raised money?"
investors can ask:
- Who invested?
- Who invested previously?
- Which investors repeatedly co-invest?
- Which sectors are attracting later-stage capital?
- Which technologies are moving toward commercialization?
- Where is capital concentrating geographically?
- Which companies are connected through investor networks?
The answers can turn individual funding announcements into a broader picture of private-market activity.
Key Takeaways From the Last Six Months
- Semiconductor startups continued to attract later-stage capital across physical AI, analog ICs, timing and interconnect technologies.
- SiMa.ai's $150 million Series C was one of the largest semiconductor rounds identified in the period.
- Stathera and AttoTude raised $55 million and $52 million respectively in Series B and Series C financing.
- Biomedical-device financing remained strongly connected to clinical, regulatory and commercialization milestones.
- CereVasc raised $85 million in Series C financing to advance its neurological device program.
- RapidPulse, Nervonik and Advanced NanoTherapies each raised Series B financing for medical technologies at different stages of clinical development.
- Series B and Series C rounds can reveal more than the amount of capital raised; they can indicate what milestone investors are financing next.
- Investor relationships and co-investment networks can provide additional context that is not visible in a funding headline.
Frequently Asked Questions
Recent examples include SiMa.ai, Celera Semiconductor, Stathera and AttoTude. Their financing supports areas including physical AI silicon, analog ICs, silicon timing and advanced interconnect technology.
Examples include CereVasc, XCath, RapidPulse, Nervonik, Advanced NanoTherapies, CroíValve and Butterfly Medical.
Later-stage capital can support product development, manufacturing, clinical trials, regulatory work, commercialization and international expansion. The precise purpose depends on the company.
Semiconductor startups generally develop chips and semiconductor-related technologies, while biomedical device startups develop technologies intended for medical diagnosis, monitoring, treatment or intervention.
Funding activity can reveal where capital is being deployed, which technologies are attracting investors, which investors are participating and what milestones companies are attempting to reach.
Sources and Research Method
This article covers publicly announced Series B and Series C financing activity identified between 1 April 2026 and 1 October 2026.
Company announcements and recent industry reporting were reviewed for individual funding amounts, financing stages, dates, investors and stated uses of proceeds.
Relevant sources reviewed include company financing announcements from SiMa.ai, Stathera, AttoTude, CereVasc and other companies discussed in this article, together with industry funding trackers covering semiconductor and medical-device financing.
Funding databases and industry publications can differ in how they classify rounds, particularly where financing includes grants, debt, strategic investment or multiple closings. Readers should verify individual transactions against primary company announcements when conducting investment research.
Go beyond the funding headline.
Explore companies, investors, funding activity and the relationships connecting private-market capital with emerging technology through InveLedger.
info@inveledger.comThis article is provided for general informational and educational purposes and does not constitute investment, financial, legal or medical advice. Funding amounts, financing classifications and company descriptions are based on publicly available information and may change as transactions are updated, amended or completed. Private-company investments involve substantial risks, including possible loss of capital and illiquidity.